Research Article
Clinical Relevance of NGAL/MMP-9 Pathway in Patients with Endometrial Cancer
Table 5
Comparative analysis according to the prognostic factors for MMP-9.
| | Mean | Median | Min | Max | |
| Endometroid/non-endometroid | 7721.5/8909.8 | 7543.6/8823.3 | 7012.6/8002.3 | 8231/9567.6 | 0.04 | G1/G2 | 5263/6789.2 | 5324.2/6881.2 | 4967.2/5122.5 | 5778.1/7657.7 | 0.061 | G1/G3 | 5263/8782.1 | 5324.2/889.2 | 4967.2/6744.5 | 5778.1/989.0 | 0.02 | FIGO I and II/FIGO III and IV | 5433.1/9213.7 | 5367/9311.7 | 4977.2/7338.4 | 6877.2/10131.8 | 0.001 | Vascular invasion (±) | 5688.3/8672.9 | 5723.3/8721.5 | 5002.9/7112.4 | 5989.7/9881.7 | 0.004 | Lymph vessels invasion (±) | 6345.2/7187.2 | 6463.1/7132.2 | 4412.5/5323.9 | 7889.2/8999.3 | 0.07 | Lymph nodes metastasis (±) | 5998.1/9141.8 | 6021/9099.3 | 5121.9/7111 | 6781.9/10267 | 0.003 | Infiltrate the myometrium superficial/deep | 6891.3/9234.8 | 6631.4/9122.4 | 5899.6/7114.8 | 7346.8/10145.6 | 0.01 |
|
|